NAPPA
Programs

Cross-border out-licensing, structured for execution.

NAPPA represents and advises licensors and licensees on cross-border biopharma deals, with a particular focus on assets moving between North America and Greater China.

Scope

What we work on.

Our active mandates span multiple therapeutic areas and stages. Specific asset listings are shared under NDA.

Therapeutic areas

Oncology · CNS · Rare disease · Cardiometabolic · Immunology

Stages

Preclinical (lead optimization onward) · Phase 1 · Phase 2 · Approved

Territories

Greater China · Asia-Pacific · U.S. · Europe (case-by-case)

Deal types

Out-licensing · In-licensing · Co-development · M&A · NewCo formation

Process

From inquiry to executed term sheet.

  1. Step 01

    Inquiry

    Submit an opportunity via the contact form. Initial response within 5 business days.

  2. Step 02

    NDA & teaser

    Mutual NDA executed. Anonymized teaser exchanged.

  3. Step 03

    Diligence

    Scientific and commercial diligence with NAPPA advisors and partners.

  4. Step 04

    Term sheet

    Structured introduction to qualified counterparties; term-sheet support.

Submit an opportunity.

Share basic information about the asset or mandate. NAPPA's BD team will respond with fit assessment and next steps. All submissions handled confidentially.

Submit opportunity